Practice Areas - Equity Capital Markets Law Firms and Lawyers
| Deal Date: | 04-06-2020 | Practice Area: | Equity Capital Markets |
| Deal Title: | Kaleido Biosciences Underwritten Offering of Common Stock | Industry: | Pharmaceuticals & Biotechnology |
| Description: |
Kaleido Biosciences, Inc., a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, closed an underwritten public offering of 4,750,000 shares of its common stock at a public offering price of USD7.50 per share. In addition, Kaleido granted the underwriters a 30-day option to purchase up to an additional 712,500 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Kaleido from this offering were approximately USD35.6 million.
Latham and Watkins LLP represented the underwriters in the offering.
|
||
| Financial Center: | New York | Value: | 0.00-100.00 |
| Advised Party: | Underwriter | Law Firm | Latham & Watkins |
| Issuer Jurisdiction - | United States | Listing Jurisdiction - | United States |
| Classification: |
Secondary Offerings and Placings NYSE: |
Lawyer | Peter Handrinos |
